BIVI ▼ -6.3% - BioVie Inc. $BIVI - BioVie Announces Topline Results from Phase 2 ADDRESS?LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID BioVie shares fell 6.3% after the company announced topline results from its Phase 2 ADDRESS-LC trial of bezisterim for treating neurological symptoms in long COVID patients. The market's negative reaction suggests investors viewed the trial outcomes as disappointing or insufficient to support the drug's advancement, though the specific efficacy or safety data would need to be reviewed in the full results announcement. 15-SEP-2026 07:30 AM ET